Clinical Trials
11 trialsNCT01989585 2026-05-13
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04557956 2026-04-02
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05275374 2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2 Not yet recruiting
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02872259 2025-01-14
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
Phase 1/2 Completed
NCT02392871 2024-11-27
CombiRT
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Completed
NCT03455764 2024-07-31
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02143050 2023-11-18
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
Phase 1/2 Withdrawn
NCT05677373 2023-08-18
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT02130466 2022-08-01
MK-3475-022
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03754179 2021-04-28
COMBI-R2
Universitair Ziekenhuis Brussel
Phase 1/2 Unknown